Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, gives an update on the QuANTUM-First study (NCT02668653) assessing quizartinib added to intensive induction and consolidation followed by single-agent continuation in patients with newly diagnosed FLT3-ITD+ acute myeloid leukemia (AML). Dr Perl explains that this study confirmed the prognostic effect of FLT3-ITD-specific measurable residual disease (MRD), and also confirmed the role of quizartinib in deepening response to treatment. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
